<i>In vivo</i> therapeutic activity of systemic tTF-NGR against CD13+ A549 tumor xenografts.
2017-06-12T17:31:30Z (GMT) by
<p>To investigate CD13 expression flow cytometry was performed with a monoclonal PE-labeled anti-CD13 antibody. CD13 expression was found in 47% of the A549 lung cancer cells (green, control; purple, CD13) (<b>Fig. 3A</b>). Following treatment with tTF-NGR (1 mg tTF-NGR/kg x4 (arrows); i.v.; n = 4 CD-1 nude mice) tumor growth of subcutaneous A549 xenotransplants was reduced as compared to the saline control group (n = 6) CD-1 nude mice (<b>Fig. 3B)</b>. The CD13 expression in subcutaneous A549 xenotransplant is demonstrated by immunofluorescence; since the antibodies used for CD13 and CD31 staining are species-specific for human CD13 and CD31, vascular and perivascular staining were not assayed in the xenografts (<b>Fig. 3C</b>).</p>
CC BY 4.0